Orange Book product · Generic (ANDA)
PYQUVI
DEFLAZACORT
At a glance
Jun 30, 2025
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jun 30, 2025
1 yr ago
Today
Pharmaceutical detail
Active ingredient
DEFLAZACORT
Strength
22.75MG/ML
Dosage form
SUSPENSION
Route
ORAL
TE code
AB
Application
ANDA 219417
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of DEFLAZACORT
- 2017EMFLAZABrand (NDA)
NDA 208685 · PTC THERAP
- 2017EMFLAZABrand (NDA)
NDA 208684 · PTC THERAP
- 2026DEFLAZACORTGeneric (ANDA)
ANDA 220709 · CARNEGIE
- 2026DEFLAZACORTGeneric (ANDA)
ANDA 219930 · SUN PHARM INDS INC
- 2025DEFLAZACORTGeneric (ANDA)
ANDA 217173 · AMNEAL
- 2025DEFLAZACORTGeneric (ANDA)
ANDA 220042 · ZYDUS LIFESCIENCES
- 2025DEFLAZACORTGeneric (ANDA)
ANDA 216992 · UPSHER SMITH LABS
- 2025JAYTHARIGeneric (ANDA)
ANDA 219254 · ZYDUS LIFESCIENCES
- 2025DEFLAZACORTGeneric (ANDA)
ANDA 217741 · SUN PHARM
- 2024DEFLAZACORTGeneric (ANDA)
ANDA 216720 · UPSHER SMITH LABS
- 2024DEFLAZACORTGeneric (ANDA)
ANDA 217813 · TRIS PHARMA INC
- 2024DEFLAZACORTGeneric (ANDA)
ANDA 217123 · AUROBINDO PHARMA LTD
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
